GLOW: Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin18.2./HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-MedSci.cn

GLOW: Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin18.2./HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Xu, RH; Ajani, JA; Al-Batran, SE; Bang, YJ; Catenacci, D; Enzinger, PC; Ilson, DH; Kim, S; Lordick, F; Shitara, K; van Cutsem, E; Arozullah, A; Park, JW; Shah, MA

ANNALS OF ONCOLOGY, 2020; 31 (): S1315

科室
- - 订阅+
  - 更多科室
工具
服务